Pharmacy coverage changes and 2026 formulary updates
October 2025| Harvard Pilgrim Health Care Commercial| Tufts Health Plan Commercial| Tufts Health Direct| Tufts Health RITogether| Tufts Health Together
The chart below identifies updates for Pharmacy Medical Necessity Guidelines. For additional details and to access the guidelines referenced below, please visit the Pharmacy Medical Necessity Guidelines page on our Point32Health provider website.
| Updates to existing prior authorization programs | |||
| Drug | Plan | Eff. date | Policy & additional information |
Asmanex HFA Asmanex Twisthaler | Harvard Pilgrim Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 1/1/2026 | Asmanex Step Therapy policy Updated step therapy program to remove Pulmicort Flexhaler. |
| Fluticasone propionate HFA | Harvard Pilgrim Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 1/1/2026 | Fluticasone propionate HFA Step Therapy Program policy Updated step therapy program to remove Pulmicort Flexhaler. |
Wegovy
Zepbound | Harvard Pilgrim Commercial, Tufts Health Plan Commercial, Tufts Health Direct | 1/1/2026 | Non-Formulary Exceptions policy
|
| Zepbound (tirzepatide) | Harvard Pilgrim Commercial, Tufts Health Plan Commercial | 1/1/2026 | Weight Loss Medications policy
|
2026 drug status and formulary updates
Please refer to this document to review drug status and formulary changes for Harvard Pilgrim Commercial, Tufts Health Plan Commercial, and Tufts Health Direct for the 2026 plan year, including:
2026 drug status and formulary updates for Tufts Health RITogether, Tufts Medicare Preferred, Tufts Health Plan Senior Care Options, and Tufts Health One Care will be announced in the November issue of Insights and Updates for Providers.